Advertisement
Screener

ORAGENICS, INC. (OGEN) Unrealized Gain (Loss) on Derivatives and Commodity Contracts

0.9 / 5 stars · 10/53 Roast Me

ORAGENICS, INC. Unrealized Gain (Loss) on Derivatives and Commodity Contracts

ORAGENICS, INC. (OGEN) reported Unrealized Gain (Loss) on Derivatives and Commodity Contracts of $188.73 thousand for the 9-month period ending 2017-09-30, per its 10-Q filed 2017-10-31.

Discontinued › Cash Flow › Operating Activities

us-gaap:UnrealizedGainLossOnDerivativesAndCommodityContracts · last filed 2017-10-31

  • ORAGENICS, INC. unrealized gain (loss) on derivatives and commodity contracts for the quarter ending 2017-09-30 was -$42.92K.
Period endUnrealized Gain (Loss) on Derivatives and Commodity Contracts 3 monthUnrealized Gain (Loss) on Derivatives and Commodity Contracts 6 monthUnrealized Gain (Loss) on Derivatives and Commodity Contracts 9 month
2017-09-30-$42.92K
derived: 10-Q 9 month − 10-Q 6 month · filed 2017-10-31
$188.73K
10-Q · filed 2017-10-31
2017-06-30$231.64K
10-Q · filed 2017-08-14

Similar stocks

Stock NameCountryMarket CapPE Ratio
JUPITER NEUROSCIENCES, INC. (JUNS)United States$0.002B-0.02
BioXcel Therapeutics, Inc. (BTAI)United States$0.002B
Nexentis Technologies Inc. (NXTS)$0.002B
Decoy Therapeutics Inc. (DCOY)United States$0.002B-0.27
ZyVersa Therapeutics, Inc. (ZVSA)United States$0.002B
Matinas BioPharma Holdings, Inc. (MTNB)United States$0.003B
Petros Pharmaceuticals, Inc. (PTPI)United States$0.003B
GeoVax Labs, Inc. (GOVX)United States$0.003B-0.45
Silo Pharma, Inc. (SILO)United States$0.003B-1.57
Genprex, Inc. (GNPX)United States$0.003B-0.02